Search

Your search keyword '"Stenner-Liewen, Frank"' showing total 4 results
Start Over Author "Stenner-Liewen, Frank" Publisher karger
4 results on '"Stenner-Liewen, Frank"'

1. Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer

Author

Zardavas, Dimitrios, Meisel, Alexander, Samaras, P, Knuth, Alexander, Renner, Christoph, Pestalozzi, Bernhard C, Stenner-Liewen, Frank, Zardavas, Dimitrios, Meisel, Alexander, Samaras, P, Knuth, Alexander, Renner, Christoph, Pestalozzi, Bernhard C, and Stenner-Liewen, Frank

Abstract

We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. After failure of two sequentially administered tyrosine kinase inhibitors, treatment with temsirolimus resulted in a prolonged partial remission of 14 months, and the response is still continuing. Up to now, no data from randomized clinical studies have been published addressing the question of efficacy of temsirolimus as third-line treatment after failure of tyrosine kinase inhibitors. The case presented here implies that temsirolimus could be a viable option for patients with metastatic chromophobe renal cell carcinoma.

Published
2011

2. Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer.

Author

Zardavas D, Meisel A, Samaras P, Knuth A, Renner C, Pestalozzi BC, and Stenner-Liewen F

Abstract

We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. After failure of two sequentially administered tyrosine kinase inhibitors, treatment with temsirolimus resulted in a prolonged partial remission of 14 months, and the response is still continuing. Up to now, no data from randomized clinical studies have been published addressing the question of efficacy of temsirolimus as third-line treatment after failure of tyrosine kinase inhibitors. The case presented here implies that temsirolimus could be a viable option for patients with metastatic chromophobe renal cell carcinoma.

Published
2011
Full Text
View/download PDF

3. Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.

Author

Samaras P, Buset EM, Siciliano RD, Haile SR, Petrausch U, Mischo A, Honegger H, Pestalozzi BC, Schanz U, Stussi G, Stahel RA, Knuth A, Renner C, and Stenner-Liewen F

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Carmustine administration & dosage, Carmustine adverse effects, Cytarabine administration & dosage, Cytarabine adverse effects, Drug Administration Schedule, Female, Filgrastim, Granulocyte Colony-Stimulating Factor administration & dosage, Hodgkin Disease surgery, Humans, Length of Stay, Lymphoma, Non-Hodgkin surgery, Male, Melphalan administration & dosage, Melphalan adverse effects, Middle Aged, Neutropenia chemically induced, Neutropenia prevention & control, Podophyllotoxin administration & dosage, Podophyllotoxin adverse effects, Polyethylene Glycols, Recombinant Proteins, Severity of Illness Index, Thrombocytopenia chemically induced, Thrombocytopenia prevention & control, Time Factors, Transplantation, Autologous, Treatment Outcome, Young Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Granulocyte Colony-Stimulating Factor therapeutic use, Hodgkin Disease drug therapy, Lymphoma, Non-Hodgkin drug therapy, Neutropenia drug therapy, Peripheral Blood Stem Cell Transplantation, Thrombocytopenia drug therapy
Abstract

Objective: To evaluate the impact of pegfilgrastim on engraftment, hospital stay and resources in patients with Hodgkin's and non-Hodgkin's lymphoma after conditioning with high-dose BEAM followed by autologous peripheral blood stem cell transplantation (APBSCT) compared with filgrastim., Methods: We reviewed patient charts and our prospective transplantation database for clinical data from the post-transplant period. An integrated cost analysis, including the use of blood products and length of hospital stay, was also performed., Results: Fourteen (26%) patients with Hodgkin's lymphoma and 40 (74%) patients with non-Hodgkin's lymphoma were analyzed. Thirty-four (68%) patients received single-dose pegfilgrastim (6 mg), and 20 (32%) patients received daily filgrastim (5 μg/kg) after APBSCT. No differences were observed regarding duration of neutropenia grade 4 (pegfilgrastim median 7 days/filgrastim median 8 days; p = 0.13), thrombocytopenia grade 4 (7/9.5 days, respectively; p = 0.21), fever (4.5/2 days; p = 0.057), intravenous antibiotic treatment (11/10 days; p = 0.75) or length of hospital stay (16.5/16 days; p = 0.27) between the groups. The use of pegfilgrastim resulted in 12% higher treatment-related costs when compared to filgrastim, without reaching statistical significance (p = 0.38)., Conclusion: Pegfilgrastim appears to be equivalent to filgrastim after high-dose BEAM followed by APBSCT in the treatment of lymphoma patients., (Copyright © 2010 S. Karger AG, Basel.)

Published
2010
Full Text
View/download PDF

4. Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients.

Author

Samaras P, Dold S, Braun J, Kestenholz P, Breitenstein S, Imhof A, Renner C, Stenner-Liewen F, and Pestalozzi BC

Subjects
Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents administration & dosage, Female, Follow-Up Studies, Hematologic Neoplasms therapy, Humans, Male, Middle Aged, Neoplasms therapy, Retrospective Studies, Risk Factors, Survival Rate, Catheterization, Central Venous instrumentation, Catheters, Indwelling microbiology, Equipment Contamination, Hematologic Neoplasms complications, Neoplasms complications, Prosthesis-Related Infections etiology
Abstract

Background: We assessed longevity and complications of totally implantable venous access devices in oncology patients., Methods: 197 patients received a total of 201 port devices via the subclavian vein for delivery of chemotherapy between January 1, 2005, and December 31, 2006. We reviewed the patient charts for port-related complications and risk factors until July 31, 2007., Results: A total of 47,781 catheter days were analyzed (median, 175 days; range, 1-831). Forty-six different complications occurred (0.96 complications/1,000 catheter days). The only risk factor significantly associated with a higher complication rate was younger age. Older patients had a lower risk for developing complications with a risk reduction of 2.4% for each year. There were no differences regarding underlying tumor, gender, access side, method of placement (subclavian/cephalic vein) or implanting team (thoracic versus visceral surgery). A trend was seen for shorter port longevity in hematologic patients compared to oncologic patients (p = 0.059). The former developed significantly more port-associated infections than solid tumor patients [11/53 cases (21%) versus 2/148 cases (1.4%); p < 0.0001]., Conclusions: Port-associated infections were mostly observed in younger patients with hematologic neoplasms. Prospective trials should be performed to evaluate the benefit of a prophylactic antimicrobial lock in these selected patients., ((c) 2008 S. Karger AG, Basel.)

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results